Substituted Quinazoline Compounds for Selective Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective small compounds that can specifically inhibit the activity of tyrosine and serine/threonine kinases to regulate abnormal cell proliferation and modulate cellular processes, particularly in the context of cancer treatment.
Innovation Solution
Development of substituted quinazoline compounds that can inhibit the activity of tyrosine and serine/threonine kinases, including those involved in EGFR mutations, by administering a therapeutically effective amount of these compounds to treat various types of cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If substituted quinazoline compounds are developed to inhibit kinase activity, then cancer treatment effectiveness is improved, but compound specificity and selectivity may be compromised
Solution Approach 1:
The patent applies local quality by designing specific substitution patterns at defined positions (R1-R5 on the quinazoline ring, R6-R10 on aromatic rings) to create distinct binding interactions with different kinase isoforms. Each substituent position is optimized to provide specific steric and electronic properties that enhance selectivity for target kinases while maintaining broad anti-cancer activity.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types (halo, alkyl, alkoxy, amino, carboxy, etc.), ring fusion patterns, and molecular weight ranges to tune the balance between kinase inhibition potency and specificity. This allows optimization of the compounds for particular kinase targets while preserving overall therapeutic effectiveness.
2Adaptability or versatility
If broad-spectrum kinase inhibition is achieved to treat multiple cancer types, then versatility in cancer treatment is improved, but off-target effects and toxicity may increase
Solution Approach 1:
The patent achieves universality by creating a quinazoline core structure that can inhibit multiple kinase families (tyrosine kinases, serine/threonine kinases) while treating various cancer types including melanoma, lung cancer, and ovarian cancer. The modular substitution pattern allows a single compound to perform multiple functions across different kinase targets.
Solution Approach 2:
The patent uses the quinazoline ring system as an intermediary structure that mediates between the need for broad kinase inhibition and the requirement for reduced off-target effects. Specific substitutions on this intermediary core allow selective engagement of desired kinase targets while avoiding harmful interactions with non-target proteins.
Data Source
AI summary
Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.